Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Diamond Shamrock Technologies S.a.

Oronzio Denora Impianti Elettrochimici S.p.a.

Other

Nec Corporation

Societa Cavi Pirelli S.p.a.

Industrie Zanussi S.p.a.

Oronzio Denora S.a.

Windtree Therapeutics, Inc.

S.e.r.e. S.r.l.

Pirelli Cavi E Sistemi S.p.a.

Enichem Synthesis S.p.a

Industrie Pirelli Societa Per Azioni

Electronor Corporation

Rostaquo S.p.a.

Giuseppe Bianchi

Patrizia Ferrari

Antonio Nidola

Alberto Cerri

Vittorio De Nora

Piero Melloni

Mara Ferrandi

Patrizio Gallone

Luigi Bernardi

Placido M Spaziante

Oronzio De Nora

Elena Folpini

Paolo Barassi

Mauro Gobbini

Marco Torri

Giulio Picierro

Saverio Niccolini

Luisa Quadri

Loredana Valentino

Maurizio Dusi

Bruno Bazzoni

Maria Pia Zappavigna

Giulio Carzana

Giorgio Fedrizzi

Gian L Mussinelli

Leonardo Banfi

Michele Orru

Riccardo Paolillo

Walter Cabri

Jens-Matthias Bohli

Nicoletta Almirante

Paolo G Priaroggia

Giuseppe Faita

Alberto Pellegri

Claudio Milocco

Giovanni Meneghini

Carlo Traini

Pietro Anelli

Oronzio DeNora

Angelo Sala

Rosamaria Micheletti

Gian N Martelli

Roberto Gonzalez Sanchez

Elio Occhini

Francesco Gringoli

Giuseppe Marazzi

Laura Gherardi

Simona Sputore

Silvia Armaroli

Antonio Capone

Antonio Zaza

Carlotta Ronchi

Marcella Rocchetti

Shih-Che Hsu

Maria Luisa Quadri

Pierluigi Gallo

Vittorio deNora

Giovanni Gussoni

Roberto Sburlino

Marco Santini

Giovanni Burei

Ilenia Tinnirello

Domenico Garlisi

Fabrizio Giuliano

Fabio Macciardi

Rosamaria Michaeletti

Alessandra Benicchio

Marco Pozzi

Barbara Moro

Maco Torri

Giuseppe Giacalone

Carmelo Cascone

Marco Bonola

Franco Valsecchi

Monica Florio

Piero Enrico Scotti

Shin-Che Hsu

Marilena Cipollaro

Amalia Forte

Francesco Rossi

Antonio Cascino

Liberato Berrino

Eleonora Torre

Francesco Peri

Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C-C) linear or branched alkyl or guanidine or guanidino (C-C) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C&#x2550;C; the thick line represents a bond in the &#x3b2; configuration; the wavy line represents a bond both in the &#x3b1; and &#x3b2; configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.

17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure

A method for data inspection includes upon receiving an out-of-order part of a sequence of parts, checking the out-of-order part for matching in forward and backward direction of the sequence; temporarily saving a forward state and a backward state of said both checkings; and upon receiving an in-order part of the sequence, checking the in-order part for matching in the forward direction of the sequence and if the in-order packet is within a gap between the first part and the last part of the sequence the in-order part is also checked for matching in backward direction of the sequence. The backward state or the forward and backward state are updated or temporarily saved.

Method and device for data inspection

The apparatus (SW) has a plurality of input/output ports (P, P, P, P, P) for receiving and transmitting data packets, and comprises a data packets handling circuitry (DPL) arranged to forward data packets between the input/output ports (P, P, P, P, P) and an internal apparatus controller (CPL) arranged to control the data packet handling circuitry (DPL); the apparatus (SW) has a control port (PC) for communication between the internal apparatus controller (CPL) and an external network controller (NWC); the apparatus controller (CPL) is arranged to store (MEM) at least one state transition table (TT) to be used for controlling the forwarding of data packets by the data packets handling circuitry (DPL); the apparatus controller (DPL) is arranged to use said at least one state transition table (TT) for implementing at least one finite state machine (FSM); the apparatus controller (DPL) is arranged to use said at least one state transition table (TT) for handling separately distinct incoming data packets flows through corresponding distinct instances of finite state machine; the apparatus controller (DPL) is arranged to receive said at least one state transition table (TT) through the control port (PC).

Method of handling data packets through a state transition table and apparatus using the same

A method for analyzing a data flow includes: (a) extracting packet information of a packet, (b) determining a status of the packet based on the extracted packet information by applying at least one probabilistic filter to the packet and storing the packet for later inspection based on the status of the packet indicating that the packet is out-of sequence, and (c) inspecting the stored packet based on inspection rules. Upon a partial match of an inspection rule with the extracted packet information, a result of the inspection is temporarily stored. Already stored packets are inspected based on the already stored packets being in-order with already inspected packets. Upon a total match of at least one of the inspection rules, a predetermined action is performed and the stored result is deleted. The at least one probabilistic filter includes a connection Bloom filter and a sequence Bloom filter.

Method and system for analyzing a data flow

A method for analyzing a data flow includes extracting packet information of a packet of the data flow, determining the status of the packet and the status of the data flow based on the extracted packet information and storing the packet for later inspection when the status of the packet and/or the status of the data flow indicate that the packet is out-of sequence, and inspecting the packet and/or the stored packet based on inspection rules. Upon a partial match of at least one of the inspection rules with the extracted packet information, a result of the inspection of the packet is temporarily stored. Already stored packets are inspected when they are in-order with already inspected packets. Upon a total match of at least one of the inspection rules, a predetermined action is performed and the stored result is deleted.

Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of proteinuria, glomerulosclerosis or renal failure.

5-&#x3b2;, 14-&#x3b2;-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure

A method for identifying potentially malicious network elements within a network is useable in a network which includes a plurality of domains administrated by different operators P1, . . . , Pn. In the method, a functional entity receives qualifying information regarding at least one network element that has been transmitted by at least some of the operators P1, . . . , Pn. The at least one network element is qualified as being potentially malicious. The functional entity provides at least one of an alarm information and an alarm activity based on a predefined number of the operators P1, . . . , Pn having transmitted the qualifying information regarding a same potentially malicious network element to the functional entity.

Method for identifying potentially malicious network elements within a network using cross-domain collaborative data sharing

Methods and systems are provided herein that are based on the effects of genetic variations on the biological activities associated to rostafuroxin in an individual. In particular, compositions, methods and systems are herein described that are based on an indentified influence on an individual response to rostafuroxin of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of KCNS3, THSD7A, FAM46A, LOC389970, HLA-G, and TTC29, and/or a genetic variation in linkage disequilibrium therewith.

Methods and systems for pharmacogenomic treatment of cardiovascular conditions

In a wireless network node, the MAC protocol is implemented through an extended finite state machine executed by the node. The operation of the wireless network node is changed by establishing a wireless connection between the present wireless network node and a remote wireless network node. One or more data packets containing a coded extended finite state machine corresponding to a specific MAC protocol are sent through the wireless connection from the remote wireless network node to the present wireless network node. An activation command from the remote wireless network node to the present wireless network node is sent through the wireless connection for activating the specific MAC protocol. This may be done during normal operation of the present wireless network node.

Method of changing the operation of wireless network nodes

The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients.

Diterpenoid derivatives endowed of biological properties

New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application. 

Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders

Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na, K-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms. 

Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders

Growing community of inventors

Milan, Italy

Giuseppe Bianchi